

DAFTAR PUSTAKA

- Adams, A. J., & Stolpe, S. F. (2016). Defining and measuring primary medication nonadherence: Development of a quality measure. *Journal of Managed Care and Specialty Pharmacy*, 22(5), 516–523. <https://doi.org/10.18553/jmcp.2016.22.5.516>
- Alfhad, H., Saftarina, F., Kurniawan, B., Kedokteran, F., Lampung, U., Ilmu, B., Komunitas, K., Kedokteran, F., & Lampung, U. (2020). Dampak Infeksi SARS-Cov-2 Terhadap Penderita Hipertensi. *Majority Journal*, 9(April), 1–5.
- Beevers, G., Lip, G. Y. H., & O'Brien, E. (2001). The Pathofisiology of Hypertension. *ABC of Hypertension*, 322(7291), 912–916. <https://doi.org/10.1136/bmj.322.7291.912>
- Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J. L., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D. M. E., van der Voort, P. H. J., Mulder, D. J., & van Goor, H. (2020). Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *Journal of Pathology*, 251(3), 228–248. <https://doi.org/10.1002/path.5471>
- Bramley, T. J., Gerbino, P. P., Nightengale, B. S., & Frech-Tamas, F. (2006). Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. *Journal of Managed Care Pharmacy*, 12(3), 239–245. <https://doi.org/10.18553/jmcp.2006.12.3.239>
- Brayfield, A., Cadart, C. R., Crehan, E. E., Eager, K., Foan, E. S., Gibbons, A. C., & Hatwal, C. S. (2014). *Martindale The Complete Drug Reference* (38th ed.). Pharmaceutical Press.
- Çelik, M., Yılmaz, Y., Karagöz, A., Kahyaoğlu, M., Özgün Çakmak, E., Küp, A., Çelik, F. B., Karaduman, A., Külahçioğlu, S., İzci, S., Geçmen, Ç., & Çalışkan, M. (2021). Anxiety Disorder Associated with the COVID-19 Pandemic Causes Deterioration of Blood Pressure Control in Primary Hypertensive Patients. *Medeniyet Medical Journal*, 36, 83–90. <https://doi.org/10.5222/mmj.2021.08364>
- Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., & Roccella, E. J. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*, 42(6), 1206–1252. <https://doi.org/10.1161/01.HYP.0000107251.49515.c2>
- Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., & Roccella, E. J. (2004). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *The JNC 7 Report*, 289(19), 2560–2571. <https://doi.org/10.1001/jama.289.19.2560>
- Chudasama, Y. V., Gillies, C. L., Zaccardi, F., Coles, B., Davies, M. J., Seidu, S., & Khunti, K. (2020). Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 14(5), 965–967.

<https://doi.org/10.1016/j.dsx.2020.06.042>

Culig, J., & Leppée, M. (2014). From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. *Collegium Antropologicum*, 38(1), 55–62. <http://www.ncbi.nlm.nih.gov/pubmed/24851597>

Daniel, W. W., & Cross, C. L. (2013). *Biostatistics: A Foundation for Analysis in the Health Sciences* (10th ed.). John Wiley & Sons. <https://doi.org/10.2307/2532686>

European Society of cardiology. (2020). ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. *European Heart Journal*, 1–115. <https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance>

Evans, L., & Spelman, M. (1983). The Problem of Non-compliance with Drug Therapy. *Drugs*, 25(1), 63–76. <https://doi.org/10.2165/00003495-198325010-00004>

Ferdinand, K. C., Vo, T. N., & Echols, M. R. (2020). State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19. *American Journal of Preventive Cardiology*, 2(June), 100038. <https://doi.org/10.1016/j.ajpc.2020.100038>

Ganiswarna, S. G. (2001). Farmakologi Dan Terapi Edisi 4. In R. Setiabudy, F. D. Suyatna, Puwentyastuti, & Nafrialdi (Eds.), *Departemen Farmakologi dan Terapeutik FKUI* (4th ed.). Gaya Baru.

Gautam, V., S. D., Rustagi, N., Mittal, A., Patel, M., Shafi, S., Thirunavukkarasu, P., & Raghav, P. (2020). Health literacy, preventive COVID 19 behaviour and adherence to chronic disease treatment during lockdown among patients registered at primary health facility in urban Jodhpur, Rajasthan. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 15(1), 205–211. <https://doi.org/10.1016/j.dsx.2020.12.023>

Guo, J., Huang, Z., Lin, L., & Lv, J. (2020). Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Journal of the American Heart Association*, 9(7), e016219. <https://doi.org/10.1161/JAHA.120.016219>

Handyani, T. E. (2011). Pengaruh Pendidikan Kesehatan terhadap Tingkat Pengetahuan dan Sikap Masyarakat tentang Pencegahan Tuberkulosis Paru di Dusun Kayangan Kecamatan Karanganyar Kabupaten Karanganyar (Skripsi). *Fakultas Ilmu Kesehatan Universitas Muhammadiyah Surakarta*, 170–179.

Hussar, D. A. (2005). Patient Compliance. In D. B. Troy, M. J. Hauber, & M. A. O'Brien, *Remington: The Science and Practice of Pharmacy*. Philadelphia: Lippincott Williams & Wilkins.

Ikawaty, R. (2020). Dinamika Interaksi Reseptor ACE2 dan SARS-CoV-2 Terhadap Manifestasi Klinis COVID-19. *KELUWIH: Jurnal Kesehatan Dan Kedokteran*, 1(2), 70–76. <https://doi.org/10.24123/kesdok.v1i2.2869>

James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C.,

Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., Smith, S. C., Svetkey, L. P., Taler, S. J., Townsend, R. R., Wright, J. T., Narva, A. S., & Ortiz, E. (2014). 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA - Journal of the American Medical Association*. <https://doi.org/10.1001/jama.2013.284427>

Kario, K., Robbins, J., & Jeffers, B. W. (2013). Titration of amlodipine to higher doses: A comparison of Asian and Western experience. *Vascular Health and Risk Management*, 9(1), 695–701. <https://doi.org/10.2147/VHRM.S50077>

Katzung, B. G., Masters, S. B., & Trevor, A. J. (2012). *Basic & Clinical Pharmacology* (12th ed.). McGrawHill.

Kementrian Kesehatan Republik Indonesia. (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/413/2020 tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). *MenKes/413/2020*. <http://www.albayan.ae>

Kementrian Kesehatan RI. (2013). *Pedoman Teknis Penemuan dan Tatalaksana Hipertensi*. Direktorat Pengendalian Penyakit Tidak Menular Subdit Pengendalian Penyakit Jantung dan Pembuluh Darah.

Kementrian Kesehatan RI. (2018). *Riset Kesehatan Dasar (RISKESDAS) Tahun 2018*. Badan Penelitian dan Pengembangan Kesehatan.

Kementrian Kesehatan RI. (2020a). *Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19)*. 1(Revisi ke-4), 1–125.

Kementrian Kesehatan RI. (2020b). *Surat Edaran Nomor: HK.01.07/I/3402/2020 tentang Penanganan Orang dengan Faktor Risiko dan Penyandang Penyakit Tidak Menular (PTM) selama Masa Pandemi COVID-19*.

Kotchen, T. A. (2012). Hypertensive Vascular Disease. In *Harisson's Principle of Internal Medicine* (18th ed.). The McGraw-Hill Companies.

Kretchy, I. A., Asiedu-Danso, M., & Kretchy, J. P. (2020). Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. *Research in Social and Administrative Pharmacy*, April, 0–1. <https://doi.org/10.1016/j.sapharm.2020.04.007>

Kripalani, S., Risser, J., Gatti, M. E., & Jacobson, T. A. (2009). Development and evaluation of the Adherence to Refills and Medications scale (ARMS) among Low-Literacy Patients with Chronic Disease. *Value in Health*, 12(1), 118–123. <https://doi.org/10.1111/j.1524-4733.2008.00400.x>

Lam, W. Y., & Fresco, P. (2015). Medication Adherence Measure: An Overview. *BioMed Research International*, 2015(Article ID 217047), 1–12. <https://doi.org/http://dx.doi.org/10.1155/2015/217047>

Lemeshow, S., Hosmer Jr, D. W., Klar, J., & Lwanga, S. K. (1990). *Adequacy of Sample Size in Health Studies*. John Wiley & Sons.

- Maryati, H. (2017). Hubungan Kadar Kolesterol dengan Tekanan Darah Penderita Hipertensi di Dusun Sidomulyo Desa Rejoagung Kecamatan Ploso Kabupaten Jombang. *Jurnal Keperawatan*, 8(2), 128–137.
- Molloy, G. J., Messerli-Bürky, N., Hutton, G., Wikman, A., Perkins-Porras, L., & Steptoe, A. (2014). Intentional and unintentional non-adherence to medications following an acute coronary syndrome: A longitudinal study. *Journal of Psychosomatic Research*, 76(5), 430–432. <https://doi.org/10.1016/j.jpsychores.2014.02.007>
- Morisky, D. E., Ang, A., & Krousel-Wood, M. (2008). Predictive validity of a medication adherence measure for hypertension control. *Journal of Clinical Hypertension*, 10(5), 348–354.
- Mounier-Vehier, C., Bernaud, C., Carré, A., Lequeuche, B., Hotton, J. M., & Charpentier, J. C. (1998). Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. *American Journal of Hypertension*, 11(4 I), 478–486. [https://doi.org/10.1016/S0895-7061\(97\)00485-8](https://doi.org/10.1016/S0895-7061(97)00485-8)
- Muhadi. (2016). JNC 8: Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa. *Cermin Dunia Kedokteran*, 43(1), 54–59.
- Notoatmodjo, S. (2012). *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta.
- Palmer, K., Monaco, A., Kivipelto, M., Onder, G., Maggi, S., Michel, J. P., Prieto, R., Sykara, G., & Donde, S. (2020). The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. *Aging Clinical and Experimental Research*, 32(7), 1189–1194. <https://doi.org/10.1007/s40520-020-01601-4>
- Pascual, J. (2000). *Hypertension Control in the Elderly with Amlodipine*. Current Medical Research and Opinion. https://www.medscape.com/viewarticle/407768_2
- Patel, K., Larson, C., Hargreaves, M., Scblundt, D., Wang, H., Jones, C., & Beard, K. (2010). Community Screening Outcomes for Diabetes, Hypertension, and Cholesterol. *J Ambulatory Care Management*, 33(2), 155–162.
- PERHI. (2019). *Konsensus Penatalaksanaan Hipertensi 2019* (A. A. Lukito, E. Harmeiwaty, & N. M. Hustrini (eds.)). Indonesian Society of Hypertension. http://www.inash.or.id/upload/event/event_Update_konsensus_2019123191.pdf
- PERKI. (2015). *Pedoman Tatalaksana Hipertensi pada Penyakit Kardiovaskular* (1st ed.). Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. <https://doi.org/10.1103/PhysRevD.42.2413>
- PERKI. (2020). Panduan Diagnosis dan Tatalaksana Penyakit Kardiovaskular pada Pandemi COVID-19. In I. Firdaus, R. Sukmawan, A. Santoso, & D. A. Juzar (Eds.), *Indonesia Heart Association* (1st ed.). Pengurus Pusat Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Pratiwi, P. I. (2016). Kepatuhan Penggunaan Obat pada Pasien Lansia dengan Penyakit Kronis (Skripsi). *Fakultas Farmasi Universitas Airlangga Surabaya*.

- Purnawan, I. N. (2019). Kepatuhan Berobat Penderita Hipertensi Di Wilayah Kerja Puskesmas Payangan Kabupaten Gianyar. *Jurnal Kesehatan Terpadu*, 3(1), 15–21. <https://doi.org/10.36002/jkt.v3i1.709>
- Rokhman, M. R., Widiastuti, M., Satibi, Fatmawati, R. F., Munawaroh, N., & Pramesti, Y. A. (2017). Penyerahan Obat Keras Tanpa Resep di Apotek. *Jurnal Manajemen Dan Pelayanan Farmasi*, 7(September), 115–124.
- Satgas Penanganan COVID-19. (2020). *Peta Sebaran COVID-19*. <https://covid19.go.id/peta-sebaran>
- Shimels, T., Kassu, R. A., Bogale, G., Bekele, M., Getnet, M., Getachew, A., Shewamene, Z., & Abraha, M. (2021). Magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Ethiopia during the COVID-19 pandemic. *PLoS ONE*, 16(4 April), 1–13. <https://doi.org/10.1371/journal.pone.0249222>
- Stirratt, M. J., Dunbar-Jacob, J., Crane, H. M., Simoni, J. M., Czajkowski, S., Hilliard, M. E., Aikens, J. E., Hunter, C. M., Velligan, D. I., Huntley, K., Ogedegbe, G., Rand, C. S., Schron, E., & Nilsen, W. J. (2015). Self-report measures of medication adherence behavior: recommendations on optimal use. *Translational Behavioral Medicine*, 5(4), 470–482. <https://doi.org/10.1007/s13142-015-0315-2>
- Sugiyono. (2019). *Metode Penelitian Kuantitatif Kualitatif dan R&D*. Bandung: Alfabeta.
- Wathaniah, N. (2017). Pengaruh Jumlah Hari Pemberian Obat Terhadap Kepatuhan dan Biaya pada Pasien Hipertensi di Puskesmas Wilayah Surabaya Pusat (Skripsi). *Fakultas Farmasi Universitas Airlangga Surabaya*.
- Wells, B. G., Dipiro, J. T., Schwinghammer, T. L., & Dipiro, C. V. (2009). Pharmacotherapy Handbook. In *The Annals of Pharmacotherapy* (7th Editio, Vol. 34, Issue 12). Mc Graw Hill. <https://doi.org/10.1345/aph.10237>
- WHO. (2003). Adherence to Long-Term Therapies: Evidence for action. In *WHO Library Cataloguing-in-Publication Data*. World Health Organization. <https://doi.org/10.1177/1049909112449068>
- WHO. (2013). A global brief on Hypertension - World Health Day 2013. *World Health Organization*, 1–40.
- WHO. (2019). *Hypertension*. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/hypertension>
- WHO. (2020a). Maintaining essential health services: operational guidance for the COVID-19 context. *Who*, 1(June), 1–61.
- WHO. (2020b). *Timeline of WHO: response to COVID-19*. World Health Organization; World Health Organization. <https://www.who.int/news-room/detail/29-06-2020-covidtimeline>
- WHO. (2020c). *WHO Coronavirus Disease (COVID-19) Dashboard*. World Health Organization.

https://covid19.who.int/%0Ahttps://covid19.who.int/region/wpro/country/cn%0Ahttps://covid19.who.int/?gclid=CjwKCAjwztL2BRATEiwAvnALcpJvfJoB2ZO9AW4cscOjOPpuNNisqVVITkpdsIGJOuXSFkrhbLCafxoCjB0QAvD_BwE%0Ahttps://covid19.who.int/region/amro/country/br

Williams, B., Mancia, G., Spiering, W., Rosei, E. A., Azizi, M., Burnier, M., Clement, D., Coca, A., De Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S., Kreutz, R., Laurent, S., ... Desormais, I. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. *European Heart Journal*, 39, 3021–3104. <https://doi.org/10.1097/HJH.0000000000001961>

Williams, H. (2015). Hypertension : pathophysiology and diagnosis. *The Pharmaceutical Journal*, 7(February), 1–9. <https://doi.org/10.1211/CP.2015.20067718>

Zainuddin, M. (2014). *Metodologi Penelitian Kefarmasian dan Kesehatan*. Surabaya: Airlangga University Press.

Zhang, X., Yu, J., Pan, L., & Jiang, H. (2020). ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. *Pharmacological Research*, 14(4)(May), 337–339. <https://doi.org/https://doi.org/10.1016/j.phrs.2020.104927> Received

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Zhibou, L., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, 395(10229), 19–21. [https://doi.org/https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/https://doi.org/10.1016/S0140-6736(20)30566-3)